Inducible T‐Cell Co‐Stimulator ( <scp>ICOS</scp> ) and <scp>ICOS</scp> Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

20252 citationsJournal Articlegold Open Access

Authors

Mina Nikanjam · University of California San Diego

Shumei Kato · University of California San Diego

Daisuke Nishizaki · University of California San Diego

Hirotaka Miyashita · Dartmouth College

Sarabjot Pabla · LabCorp (United States)

Mary Nesline · LabCorp (United States)

Heidi Ko

Abstract

Biomarker-driven approaches will be important to individualize therapy and ascertain which cancer patients will derive the greatest benefit from ICOS-directed combination therapy approaches.

Topics & Keywords

Microbial metabolism and enzyme function Neutrophil, Myeloperoxidase and Oxidative Mechanisms Cancer Immunotherapy and Biomarkers

Publication Details

Published in: Cancer Medicine

Volume 15, Issue 1, pp. e71467-e71467

DOI: 10.1002/cam4.71467

Field-Weighted Citation Impact: 1.65

Command Palette

Inducible T‐Cell Co‐Stimulator ( <scp>ICOS</scp> ) and <scp>ICOS</scp> Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Authors

Abstract

Topics & Keywords

Publication Details